Technical Analysis for ALRN - Aileron Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Centerline Cross | Bearish | 0.00% | |
| Expansion Pivot Sell Setup | Bearish Swing Setup | 0.00% | |
| Wide Range Bar | Range Expansion | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% |
| Alert | Time |
|---|---|
| 3x Volume Pace | 1 day ago |
| 60 Minute Opening Range Breakdown | 1 day ago |
| Down 10% | 1 day ago |
| Down 1 ATR | 1 day ago |
| 2x Volume Pace | 1 day ago |
Get a Trading Assistant
- Earnings date: 11/04/2024
Aileron Therapeutics, Inc. Description
Aileron Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation. The Company is advancing its lead oncology program to deliver efficacy and safety in a spectrum of solid and hematological malignancies. Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. ALRN-6924 may reactivate p53-mediated cell death by targeting both of the natural p53 suppressor proteins, Mouse double minute 2 homolog (MDM2) and MDMX.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Biology Solid Tumors Tumor Inflammation Molecular Biology Lymphoma Cell Biology Metabolic Disease Oncogenes Peptides Hematological Malignancies Proteins P53 Tumor Suppressor Genes Treatment Of A Range Of Cancer Tumor Suppressor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.42 |
| 52 Week Low | 1.61 |
| Average Volume | 87,044 |
| 200-Day Moving Average | 3.78 |
| 50-Day Moving Average | 3.48 |
| 20-Day Moving Average | 3.74 |
| 10-Day Moving Average | 3.65 |
| Average True Range | 0.36 |
| RSI (14) | 33.33 |
| ADX | 17.45 |
| +DI | 11.23 |
| -DI | 26.82 |
| Chandelier Exit (Long, 3 ATRs) | 3.33 |
| Chandelier Exit (Short, 3 ATRs) | 3.74 |
| Upper Bollinger Bands | 4.30 |
| Lower Bollinger Band | 3.17 |
| Percent B (%b) | -0.27 |
| BandWidth | 30.28 |
| MACD Line | -0.04 |
| MACD Signal Line | 0.08 |
| MACD Histogram | -0.1188 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.05 | ||||
| Resistance 3 (R3) | 4.11 | 3.78 | 3.85 | ||
| Resistance 2 (R2) | 3.78 | 3.48 | 3.75 | 3.79 | |
| Resistance 1 (R1) | 3.33 | 3.30 | 3.16 | 3.26 | 3.72 |
| Pivot Point | 3.00 | 3.00 | 2.92 | 2.97 | 3.00 |
| Support 1 (S1) | 2.54 | 2.70 | 2.38 | 2.48 | 2.02 |
| Support 2 (S2) | 2.21 | 2.51 | 2.18 | 1.95 | |
| Support 3 (S3) | 1.76 | 2.21 | 1.89 | ||
| Support 4 (S4) | 1.69 |
